Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Žigon, Polona ^a   Perdan Pirkmajer, Katja ^a   Tomšič, Matija ^a   Kveder, Tanja ^a   Božič, Borut ^a,b   Sodin Šemrl, Snežna ^a,c   Čučnik, Saša ^a   Ambrožič, Aleš ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c UNIVERSITY OF PRIMORSKA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE ANTIBODY; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PROTHROMBIN;

ADULT; ADVERSE OUTCOME; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; ECLAMPSIA; FEMALE; FETUS DEATH; GESTATION PERIOD; HUMAN; MAJOR CLINICAL STUDY; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; RECURRENT ABORTION; SPONTANEOUS ABORTION; CASE CONTROL STUDY; IMMUNOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS; PREVALENCE;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHATIDYLSERINES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREVALENCE; PROTHROMBIN;

EID: 84930959217     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/975704     Document Type: Article

References (39)

1. S. Miyakis, M. D. Lockshin, T. Atsumi et al., "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)," Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295-306, 2006.
2. M. Galli, "Anti-prothrombin antibodies," in The Antiphospholipid Syndrome II, R. A. Asherson, R. Cervera, J. C. Piette, and Y. Shoenfeld, Eds., pp. 59-70, Elsevier, New York, NY, USA, 2002.
3. L. Marozio, A. Curti, G. Botta et al., "Anti-prothrombin antibodies are associated with adverse pregnancy outcome," American Journal of Reproductive Immunology, vol. 66,no. 5, pp. 404-409, 2011.
4. S. Sciascia, G. Sanna, V. Murru, D. Roccatello, M. A. Khamashta, and M. L. Bertolaccini, "Anti-prothrombin (aPT) and antiphosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome a systematic review," Thrombosis and Haemostasis, vol. 111, no. 2, pp. 354-364, 2013.
5. T. Atsumi, O. Amengual, S. Yasuda, and T. Koike, "Antiprothrombin antibodies - are they worth assaying?" Thrombosis Research, vol. 114, no. 5-6, pp. 533-538, 2004.
6. M. L. Bertolaccini, O. Amengual, T. Atsumi et al., "'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010," Lupus, vol. 20, no. 2, pp. 191-205, 2011.
7. A. Ghirardello, N. Bizzaro, S. Zampieri et al., "Biological and clinical relevance of anti-prothrombin antibodies," Annals of the New York Academy of Sciences, vol. 1109, pp. 503-510, 2007.
8. M. Galli and T. Barbui, "Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome," Blood, vol. 93, no. 7, pp. 2149-2157, 1999.
9. M. L. Bertolaccini, S. Sciascia, V. Murru, C. Garcia-Fernandez, G. Sanna, and M. A. Khamashta, "Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant," Thrombosis and Haemostasis, vol. 109, no. 2, pp. 207-213, 2013.
10. O. Amengual, T. Atsumi, and T. Koike, "Specificities, properties, and clinical significance of antiprothrombin antibodies," Arthritis and Rheumatism, vol. 48, no. 4, pp. 886-895, 2003.
11. P. Zigon, A. Ambrozic, S. Cucnik, T. Kveder, B. Rozman, and B. Bozic, "Modified phosphatidylserine-dependent antiprothrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies," Clinical Chemistry and Laboratory Medicine, vol. 49, no. 9, p. 1573, 2011.
12. R. R. Forastiero, M. E. Martinuzzo, G. S. Cerrato, L. C. Kordich, and L. O. Carreras, "Relationship of anti β2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies," Thrombosis and Haemostasis, vol. 78, no. 3, pp. 1008-1014, 1997.
13. J. Nojima, Y. Iwatani, E. Suehisa, H. Kuratsune, and Y. Kanakura, "The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus," Haematologica, vol. 91, no. 5, pp. 699-702, 2006.
14. M. S. Sater, R. R. Finan, F. M. Abu-Hijleh, T. M. Abu-Hijleh, and W. Y. Almawi, "Anti-phosphatidylserine, anti-cardiolipin, anti-β2 glycoprotein I and anti-prothrombin antibodies in recurrent miscarriage at 8-12 gestational weeks," European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 163, no. 2, pp. 170-174, 2012.
15. M. Sugiura-Ogasawara, T. Atsumi, Y. Ozaki, T. Koike, and K. Suzumori, "Phosphatidylserine-dependent antiprothrombin antibodies are not useful markers for high-risk women with recurrent miscarriages," Fertility and Sterility, vol. 82, no. 5, pp. 1440-1442, 2004.
16. A. Tsutsumi, T. Atsumi, H. Yamada et al., "Anti-phosphatidylserine/prothrombin antibodies are not frequently found in patients with unexplained recurrent miscarriages," The American Journal of Reproductive Immunology, vol. 46, no. 3, pp. 242-244, 2001.
17. T. Akimoto, T. Akama, M. Saitoh, I. Kono, and T. Sumida, "Antiprothrombin autoantibodies in severe preeclampsia and abortion," The American Journal of Medicine, vol. 110, no. 3, pp. 188-191, 2001.
18. M. L. Bertolaccini, T. Atsumi, T. Koike, G. R. V. Hughes, and M. A. Khamashta, "Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus," Thrombosis and Haemostasis, vol. 93, no. 2, pp. 289-297, 2005.
19. A. Vlagea, A. Gil, M. V. Cuesta et al., "Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome," Clinical and Applied Thrombosis/Hemostasis, vol. 19, no. 3, pp. 289-296, 2013.
20. P. Žigon, S. Čučnik, A. Ambrožič et al., "Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value," Clinical and Developmental Immunology, vol. 2013, Article ID 724592, 8 pages, 2013.
21. L. Sabatini, M. Torricelli, V. Scaccia et al., "Increased plasma concentrations of antiprothrombin antibodies in women with recurrent spontaneous abortions," Clinical Chemistry, vol. 53, no. 2, pp. 228-232, 2007.
22. J. T. Brandt, D. A. Triplett, B. Alving, and I. Scharrer, "Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH," Thrombosis and Haemostasis, vol. 74, no. 4, pp. 1185-1190, 1995.
23. T. Exner, G. Papadopoulos, and J. Koutts, "Use of a simplified dilute Russell's viper venom time (DRVVT) confirms heterogeneity among 'lupus anticoagulants'," Blood Coagulation & Fibrinolysis, vol. 1, no. 3, pp. 259-266, 1990.
24. B. Bozic, T. Kveder, M. Stegnar et al., "Influence of degraded phosphatidylserine on binding of antiphospholipid antibodies," International Archives of Allergy and Immunology, vol. 112, no. 1, pp. 19-26, 1997.
25. S. Čučnik, I. Križaj, B. Rozman, T. Kveder, and B. Božič, "Concomitant isolation of protein C inhibitor and unnicked β2-glycoprotein I," Clinical Chemistry and Laboratory Medicine, vol. 42, no. 2, pp. 171-174, 2004.
26. Y. Shoenfeld, H. J. A. Carp, V. Molina et al., "Autoantibodies and prediction of reproductive failure," American Journal of Reproductive Immunology, vol. 56, no. 5-6, pp. 337-344, 2006.
27. C. A. Clark, C. A. Laskin, and K. A. Spitzer, "Anticardiolipin antibodies and recurrent early pregnancy loss: a century of equivocal evidence," Human Reproduction Update, vol. 18, no. 5, Article ID dms020, pp. 474-484, 2012.
28. L. Andreoli, C. B. Chighizola, A. Banzato, G. J. Pons-Estel, G. R. De Jesus, and D. Erkan, "Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis," Arthritis Care and Research, vol. 65, no. 11, pp. 1869-1873, 2013.
29. K. Abou-Nassar, M. Carrier, T. Ramsay, and M. A. Rodger, "The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis," Thrombosis Research, vol. 128, no. 1, pp. 77-85, 2011.
30. C. A. Clark, J. Davidovits, K. A. Spitzer, and C. A. Laskin, "The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic," Blood, vol. 122, no. 3, pp. 341-347, 466, 2013.
31. K. Otomo, T. Atsumi, O. Amengual et al., "Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events," Arthritis & Rheumatism, vol. 64, no. 2, pp. 504-512, 2012.
32. J. L. Kujovich, "Thrombophilia and pregnancy complications," American Journal of Obstetrics and Gynecology, vol. 191, no. 2, pp. 412-424, 2004.
33. M. Blank and Y. Shoenfeld, "Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome," Clinical Reviews in Allergy and Immunology, vol. 38, no. 2-3, pp. 141-147, 2010.
34. K. Oku, O. Amengual, and T. Atsumi, "Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome," European Journal of Clinical Investigation, vol. 42, no. 10, pp. 1126-1135, 2012.
35. S. T. Matalon, Y. Shoenfeld, M. Blank, S. Yacobi, P. von Landenberg, and A. Ornoy, "Antiphosphatidylserine antibodies affect rat yolk sacs in culture: a mechanism for fetal loss in antiphospholipid syndrome," American Journal of Reproductive Immunology, vol. 51, no. 2, pp. 144-151, 2004.
36. W. Y. Sun, D. P. Witte, J. L. Degen et al., "Prothrombin deficiency results in embryonic and neonatal lethality in mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7597-7602, 1998.
37. K. Bramham, B. J. Hunt, S. Germain et al., "Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome," Lupus, vol. 19, no. 1, pp. 58-64, 2010.
38. T. Marchetti, M. Cohen, and P. de Moerloose, "Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications," Clinical and Developmental Immunology, vol. 2013, Article ID 159124, 9 pages, 2013.
39. Z. Ulcova-Gallova, V. Krauz, P. Novakova et al., "Antiphospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only," American Journal of Reproductive Immunology, vol. 54, no. 2, pp. 112-117, 2005.